Abnormal inhibin A and inhibin B secretion in obese women with and without insulin resistance

Gynecological Endocrinology

Volumn 21, Issue 1, 2005, Pages 7-11

  Auge, Antonio Pedro ^a,b   Longui, Carlos Alberto ^a   Prado, Roberto A Almeida ^a   Neves, Mylene Rocha ^a   Hirota, Andrea ^a   Busso, Newton Eduardo ^a   Monte, Osmar ^a   Aldrighi, José Mendes ^a  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Anovulation; Follicular luteinization; Inhibin; Insulin resistance; Obesity

Indexed keywords

INHIBIN A; INHIBIN B; PROGESTERONE;

ADOLESCENT; ADULT; ANOVULATION; ARTICLE; BODY MASS; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE RELEASE; HUMAN; INSULIN RESISTANCE; LUTEAL PHASE; LUTEINIZATION; MEASUREMENT; MENSTRUAL CYCLE; MENSTRUATION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY FOLLICLE DEVELOPMENT; OVULATION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; BODY MASS INDEX; FEMALE; FOLLICLE STIMULATING HORMONE; GLUCOSE TOLERANCE TEST; HUMANS; INHIBINS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LUTEINIZING HORMONE; MENSTRUAL CYCLE; MIDDLE AGED; OBESITY; OVULATION; PROGESTERONE; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN;

EID: 23244440143     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590500128716     Document Type: Article

References (19)

1. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Geneva: WHO; 2000. 253 p. (WHO Technical Report series; no. 894).
2. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956;4:20-34.
3. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982;54:254-60.
4. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Br Med J 1995;311:1401-5.
5. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
6. Smith SC Jr, Clark LT, Cooper RS, Daniels SR, Kumanyika SK, Ofili E, Quinones MA, Sanchez EJ, Saunders E, Tiukinhoy SD; American Heart Association Obesity, Metabolic Syndrome, and Hypertension Writing Group. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003:report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation 2005;111:e134-9.
7. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996;81:302-9.
8. Nikolaou D, Gilling-Smith C. Early ovarian ageing: are women with polycystic ovaries protected? Hum Reprod 2004;19:2175-9.
9. Nagamani M, Stuart CA. Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis. Am J Obstet Gynecol 1990;163:1992-7.
10. Saleh A M, Khalil HS. Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2004;83:614-21.
11. Pigny P, Desailloud R, Cortet-Rudelli C, Duhamel A, Deroubaix-Allard D, Racadot A, Dewailly D. Serum α-inhibin levels in polycystic ovary syndrome: relationship to the serum androstenedione level. J Clin Endocrinol Metab 1997;82: 1939-43.
12. Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab 1998;83:1730-5.
13. Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B, Duhamel A, Dewailly D. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism. Fertil Steril 2000;73:972-7.
14. Hohmann FP, Laven JSE, de Jong FH, Fauser BCJM. Relationship between inhibin A and B, estradiol and follicle growth dynamics during ovarian stimulation in normo-ovulatory women. Eur J Endocrinol 2005;152:395-401.
15. Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 1991;73:590-5.
16. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401-5.
17. Groome NP, Illingworth PJ, O'Brien M, Cooke I, Ganesan TS, Baird DT, McNeilly AS. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol (Oxf) 1994;40:717-23.
18. Sehested A, Juul AA, Andersson AM, Petersen JH, Jensen TK, Muller J, Skakkebaek NE. Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels. J Clin Endocrinol Metab 2000;85:1634-40.
19. Cortet-Rudelli C, Pigny P, Decanter C, Leroy M, Maunoury-Lefebvre C, Thomas-Desrousseaux P, Dewailly D. Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome. Fertil Steril 2002;77:281-7.